Antibiotic Focus Tetraphase is a small biotech dedicated to combatting antimicrobial resistance with a leadership product, XERAVA, and a mission to make novel antibiotics accessible to patients in need, signaling ongoing relevance for partnerships in infectious disease care.

Regulatory Milestone Lead product XERAVA is approved for complicated intra-abdominal infections, presenting a tangible reference point for case-based selling, clinical adoption discussions, and potential expansions into related indications or hospital formularies.

Strategic Partners Historically active in partnerships and mergers with companies like La Jolla, AcelRx, and Melinta, indicating a track record of collaboration and potential for co-development or distribution deals to extend market reach.

Financial Footing Revenue currently in the low multi-million range with substantial funding (~$99M), suggesting capacity for value-based deals, access programs, and strategic investments to accelerate adoption of XERAVA in targeted hospital networks.

Operational Footprint Small team size (11-50 employees) and a tech-enabled digital presence imply agility and responsiveness, enabling targeted outreach to mid-to-large healthcare systems, VA/CHCs, and specialty distributors through streamlined, focused BD efforts.